MedPath

Study of AGN-190584 Eye Drops to Assess Safety and Efficacy in Participants Aged 40-80 Years With Pseudophakic Presbyopia

Phase 2
Withdrawn
Conditions
Presbyopia
Interventions
Drug: Vehicle
Drug: AGN-190584
Registration Number
NCT05393089
Lead Sponsor
Allergan
Brief Summary

Presbyopia is a condition in which the eye exhibits a diminished ability to focus on near objects with increasing age. This study will assess the safety and exploratory efficacy of AGN-190584 is in treating participants with pseudophakic presbyopia.

AGN-190584 is approved (in the United States) for use in adults with presbyopia (including those who are pseudophakic) and this study is being conducted to better understand the safety and efficacy in the pseudophakic presbyopia population. This study is double-masked meaning that neither the participants nor the study doctors will know who will be given AGN-190584 and who will be given vehicle (does not contain treatment drug). Study doctors put the participants in 1 of the 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 3 chance that participants will be assigned to vehicle. Approximately 150 participants aged 40-80 years with pseudophakic presbyopia will be enrolled in approximately 30 sites in the US.

Participants will receive eye drops of AGN-190584 or vehicle once daily in the morning in each eye for 14 days.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study. The effect of the treatment will be evaluated by medical assessments, checking for side effects and completing questionnaires.

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • History of bilateral pseudophakia with monofocal intraocular lenses corrected for distance (noncomplicated cataract surgery), with identifiable intraocular lens type/brand, at least 3 months after surgery (prior to baseline), and be in stable condition.
  • If a participant has had neodymium-doped yttrium aluminum garnet (Nd:YAG) laser capsulotomy, it needs to be done bilaterally at least 1 month prior to baseline.
  • Subjective complaints of poor near vision that impacts activities of daily living, as defined by at least a moderate impact (score >= 3) on at least 1 question on 25-Item National Eye Institute Visual Function Questionnaire (NEI VFQ-25) Questions 5 to 7 in the main questionnaire or Near Vision Subscale, Questions A3 to A5 in the Appendix of Optional Additional Questions at the screening visit.
  • Best distance correction at screening in the range of spherical -1.50 D to +1.00 D inclusively and cylinder <= ±2.00 D with photopic high contrast binocular corrected distance visual acuity (CDVA) of 20/25 or better at the screening and baseline visits.
  • Mesopic, high contrast binocular distance-corrected near visual acuity (DCNVA) no better than 20/40 (J3) at screening and baseline visits.
Read More
Exclusion Criteria
  • Presence of any ocular condition that, in the opinion of the investigator, could affect the safety of the participant or interpretation of efficacy parameters (e.g., uveitis, acute iritis, retinal detachment or retinal tear).
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
VehicleVehicleParticipants will receive one drop of vehicle instilled in each eye once daily for 14 days.
AGN-190584AGN-190584Participants will receive one drop of AGN-190584 instilled in each eye once daily for 14 days.
Primary Outcome Measures
NameTimeMethod
Number of Participants Experiencing Adverse Events (AEs)Up to approximately 14 days

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (32)

Global Research Management /ID# 243544

🇺🇸

Glendale, California, United States

United Medical Research Institute /ID# 243531

🇺🇸

Inglewood, California, United States

Salvay Vision /ID# 243828

🇺🇸

Newport Beach, California, United States

The Eye Research Foundation /ID# 243524

🇺🇸

Newport Beach, California, United States

Sacramento Eye Consultants /ID# 243538

🇺🇸

Sacramento, California, United States

Segal Drug Trials, Inc /ID# 243521

🇺🇸

Delray Beach, Florida, United States

Arizona Eye Center /ID# 243897

🇺🇸

Chandler, Arizona, United States

Levenson Eye Associates Inc. /ID# 243532

🇺🇸

Jacksonville, Florida, United States

Kannarr Eye Care /ID# 243542

🇺🇸

Pittsburg, Kansas, United States

Key-Whitman Eye Center /ID# 243928

🇺🇸

Dallas, Texas, United States

Eye associates /ID# 243526

🇺🇸

San Antonio, Texas, United States

Cincinnati Eye Institute- Edgewood /ID# 243810

🇺🇸

Edgewood, Kentucky, United States

EyeCare Professionals Inc /ID# 243938

🇺🇸

Powell, Ohio, United States

Scott and Christie and Associates /ID# 243548

🇺🇸

Cranberry Township, Pennsylvania, United States

Silverstein Eye Centers /ID# 243546

🇺🇸

Kansas City, Missouri, United States

University Eye Surgeons /ID# 243926

🇺🇸

Maryville, Tennessee, United States

Advancing Vision Research /ID# 243529

🇺🇸

Smyrna, Tennessee, United States

Fraser Eye Center /ID# 244038

🇺🇸

Fraser, Michigan, United States

Country Hills Eye Center /ID# 243520

🇺🇸

Ogden, Utah, United States

Hoopes, Durrie, Rivera Research /ID# 243535

🇺🇸

Draper, Utah, United States

Southern Utah Medical Research /ID# 243931

🇺🇸

Saint George, Utah, United States

Clayton Eye Clinical Research, LLC /ID# 243530

🇺🇸

Morrow, Georgia, United States

Coastal Research Associates /ID# 243525

🇺🇸

Roswell, Georgia, United States

Emory University /ID# 243534

🇺🇸

Atlanta, Georgia, United States

Nature Coast Clinical Research - Crystal River /ID# 243519

🇺🇸

Crystal River, Florida, United States

Rochester Ophthalmological Group PC /ID# 243539

🇺🇸

Rochester, New York, United States

The Eye Care Institute /ID# 243588

🇺🇸

Louisville, Kentucky, United States

Parkhurst Nuvision /ID# 244041

🇺🇸

San Antonio, Texas, United States

Eye Associates of North Jersey /ID# 243913

🇺🇸

Dover, New Jersey, United States

Northern New Jersey Eye Institute PA /ID# 243522

🇺🇸

South Orange, New Jersey, United States

Trinity Research Group /ID# 243541

🇺🇸

Dothan, Alabama, United States

Eye Associates of Fort Meyers /ID# 243545

🇺🇸

Fort Myers, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath